Evidence map›Paper›PMID 34122106›Full record

ReviewFrontiers in pharmacology2021

The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions.

Shahin Shams, Joseph M Martinez, John R D Dawson, Juan Flores, Marina Gabriel, Gustavo Garcia, Amanda Guevara, Kaitlin Murray, Noah Pacifici, Maxemiliano V Vargas and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shahin ShamsDepartment of Biomedical Engineering, University of California, Davis, Davis, CA, United States.
Joseph M MartinezDepartment of Pharmacology, University of California, Davis, Davis, CA, United States.
John R D DawsonDepartment of Physiology and Membrane Biology, University of California, Davis, Davis, CA, United States.
Juan FloresCenter for Neuroscience, University of California, Davis, Davis, CA, United States.
Marina GabrielDepartment of Biomedical Engineering, University of California, Davis, Davis, CA, United States.
Gustavo GarciaDepartment of Biomedical Engineering, University of California, Davis, Davis, CA, United States.
Amanda GuevaraDepartment of Pharmacology, University of California, Davis, Davis, CA, United States.
Kaitlin MurrayDepartment of Anatomy, Physiology, and Cell Biology, University of California, Davis, Davis, CA, United States.
Noah PacificiDepartment of Biomedical Engineering, University of California, Davis, Davis, CA, United States.
Maxemiliano V VargasDepartment of Chemistry, University of California, Davis, Davis, CA, United States.
Taylor VoelkerDepartment of Physiology and Membrane Biology, University of California, Davis, Davis, CA, United States.
Johannes W HellDepartment of Pharmacology, University of California, Davis, Davis, CA, United States.
Judith F AshouriRosalind Russell and Ephraim R. Engleman Rheumatology Research Center, Department of Medicine, University of California, San Francisco, CA, United States.

Funding

Training Program In Basic & Translational Cardiovascular ScienceT32HL086350 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Martin Cadeiras, David A. Liem · 2008 to 2026
$7.1M
Predoctoral Training in Pharmacological SciencesT32GM099608 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HELL, JOHANNES W · 2012 to 2021
$2.2M
Adrenergic Signaling in the CNS in Health and DiseaseF99NS120523 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MARTINEZ, JOSEPH M · 2020 to 2021
$79k
6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is a debilitating autoimmune disease with grave physical, emotional and socioeconomic consequences. Despite advances in targeted biologic and pharmacologic interventions that have recently come to market, many patients with RA continue to have inadequate response to therapies, or intolerable side effects, with resultant progression of their disease. In this review, we detail multiple biomolecular pathways involved in RA disease pathogenesis to elucidate and highlight pathways that have been therapeutic targets in managing this systemic autoimmune disease. Here we present an up-to-date accounting of both emerging and approved pharmacological treatments for RA, detailing their discovery, mechanisms of action, efficacy, and limitations. Finally, we turn to the emerging fields of bioengineering and cell therapy to illuminate possible future targeted therapeutic options that combine material and biological sciences for localized therapeutic action with the potential to greatly reduce side effects seen in systemically applied treatment modalities.

Indexed as

adenosine receptorautoimmune diseasebiological therapiesdisease modifying anti-rheumatic drugsinflammatory cytokines and chemokinesJAK-STAT signalingnanoparticlesrheumatoid arthritis

Identifiers

PMID34122106
PMCPMC8194305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.